Pulse Biosciences (PLSE) 10-Q 7 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	Pulse Biosciences, Inc.
Entity Filer Category	Accelerated Filer
Entity Central Index Key	0001625101
Amendment Flag	false
Document Type	10-Q
Document Fiscal Period Focus	Q3
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Current Fiscal Year End Date	--12-31
Trading Symbol	PLSE
Title of 12(b) Security	Common Stock, par value $0.001 per share
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,788,149

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 9,570	$ 51,103
Investments	24,928	8,480
Prepaid expenses and other current assets	1,437	779
Total current assets	35,935	60,362
Property and equipment, net	2,428	2,173
Intangible assets, net	4,713	5,213
Goodwill	2,791	2,791
Right-of-use assets	1,190
Other asset	1,645	101
Total assets	48,702	70,640
Current liabilities:
Accounts payable	1,816	1,272
Accrued expenses	2,054	1,421
Deferred rent, current		415
Lease liability, current	177
Total current liabilities	4,047	3,108
Deferred rent, net of current		1,198
Lease liability, net of current	3,674
Total liabilities	7,721	4,306
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding
Common stock, $0.001 par value: authorized – 500,000 shares; issued and outstanding – 20,788 shares and 20,593 shares at September 30, 2019 and December 31, 2018, respectively	21	21
Additional paid-in-capital	149,853	142,032
Accumulated other comprehensive income (loss)	8	(1)
Accumulated deficit	(108,901)	(75,718)
Total stockholders' equity	40,981	66,334
Total liabilities and stockholders' equity	$ 48,702	$ 70,640

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Condensed Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,788,000	20,593,000
Common stock, shares outstanding	20,788,000	20,593,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations And Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Condensed Consolidated Statements Of Operations And Comprehensive Loss [Abstract]
Revenue
Operating expenses:
General and administrative	5,606	5,675	15,153	16,230
Research and development	6,192	5,038	18,371	12,174
Amortization of intangible assets	166	166	500	499
Total operating expenses	11,964	10,879	34,024	28,903
Other income (expense):
Interest income	218	118	841	311
Total other income (expense)	218	118	841	311
Net loss	(11,746)	(10,761)	(33,183)	(28,592)
Other comprehensive loss:
Unrealized gain (losses) on available-for-sale securities	(14)	(3)	9	48
Comprehensive loss	$ (11,760)	$ (10,764)	$ (33,174)	$ (28,544)
Net loss per share:
Basic and diluted net loss per share	$ (0.57)	$ (0.64)	$ (1.60)	$ (1.69)
Weighted average shares used to compute net loss per common share - basic and diluted	20,774	16,927	20,728	16,883

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (33,183)	$ (28,592)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	390	474
Amortization of intangible assets	500	499
Stock-based compensation	7,739	9,988
Net premium amortization on investments	(458)	(100)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(658)	(683)
Accounts payable	544	499
Accrued expenses	633	623
Other assets	(2,734)
Other current and non-current liabilities	2,238	(296)
Net cash used in operating activities	(24,989)	(17,588)
Cash flows from investing activities:
Purchases of property and equipment	(645)	(243)
Purchases of investments	(72,981)	(39,799)
Maturities of investments	57,000	35,065
Sales of investments		24,875
Net cash provided by (used in) investing activities	(16,626)	19,898
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock purchase plan	423	327
Tax payments related to shares withheld for vested restricted stock units	(613)	(115)
Proceeds from exercises of stock options	272	423
Net cash provided by financing activities	82	635
Net increase (decrease) in cash and cash equivalents	(41,533)	2,945
Cash and cash equivalents at beginning of period	51,103	3,386
Cash and cash equivalents at end of period	9,570	6,331
Supplemental disclosure of noncash investing and financing activities:
Change in unrealized gains (losses) on available-for-sale securities	9	48
Equipment purchased in accounts payable and accrued expenses	$ 219	$ 39

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common StockWarrants [Member]	Common Stock	Additional Paid-in Capital [Member]Warrants [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]Warrants [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]Warrants [Member]	Accumulated Deficit [Member]	Warrants [Member]	Total
Balance at Dec. 31, 2017		$ 17		$ 84,202		$ (51)		$ (38,173)		$ 45,995
Balance, shares at Dec. 31, 2017		16,819
Issuance of shares upon exercise of stock options				423						423
Issuance of shares upon exercise of stock options, shares	24	117
Issuance of shares under employee stock purchase plan				327						327
Issuance of shares under employee stock purchase plan, shares		24
Stock-based compensation expense				9,988						9,988
Tax payments related to shares withheld for vested restricted stock units				(115)						(115)
Unrealized gains (losses) on available-for-sale securities						48				48
Net loss								(28,592)		(28,592)
Balance at Sep. 30, 2018		$ 17		94,825		(3)		(66,765)		28,074
Balance, shares at Sep. 30, 2018		16,984
Balance at Jun. 30, 2018		$ 17		91,034				(56,004)		35,047
Balance, shares at Jun. 30, 2018		16,886
Issuance of shares upon exercise of stock options				258						258
Issuance of shares upon exercise of stock options, shares	24	62
Issuance of shares under employee stock purchase plan				139						139
Issuance of shares under employee stock purchase plan, shares		12
Stock-based compensation expense				3,394						3,394
Unrealized gains (losses) on available-for-sale securities						(3)				(3)
Net loss								(10,761)		(10,761)
Balance at Sep. 30, 2018		$ 17		94,825		(3)		(66,765)		28,074
Balance, shares at Sep. 30, 2018		16,984
Balance at Dec. 31, 2018		$ 21		142,032		(1)		(75,718)		$ 66,334
Balance, shares at Dec. 31, 2018		20,593								20,593
Issuance of shares upon exercise of stock options				272						$ 272
Issuance of shares upon exercise of stock options, shares		99
Issuance of shares under employee stock purchase plan				423						423
Issuance of shares under employee stock purchase plan, shares		38
Issuance of shares upon vesting of restriced stock units
Issuance of shares upon vesting of restriced stock units, shares		58
Stock-based compensation expense				7,739						7,739
Tax payments related to shares withheld for vested restricted stock units				(613)						(613)
Unrealized gains (losses) on available-for-sale securities						9				9
Net loss								(33,183)		(33,183)
Balance at Sep. 30, 2019		$ 21		149,853		8		(108,901)		$ 40,981
Balance, shares at Sep. 30, 2019		20,788								20,788
Balance at Jun. 30, 2019		$ 21		146,973		22		(97,155)		$ 49,861
Balance, shares at Jun. 30, 2019		20,768
Issuance of shares under employee stock purchase plan				201						201
Issuance of shares under employee stock purchase plan, shares		20
Stock-based compensation expense				2,679						2,679
Unrealized gains (losses) on available-for-sale securities						(14)				(14)
Net loss								(11,746)		(11,746)
Balance at Sep. 30, 2019		$ 21		$ 149,853		$ 8		$ (108,901)		$ 40,981
Balance, shares at Sep. 30, 2019		20,788								20,788

Description Of The Business

Description Of The Business	9 Months Ended
	Sep. 30, 2019
Description Of The Business [Abstract]
Description Of The Business	1. Description of the Business  Pulse Biosciences, Inc. is a novel bioelectric medicine company committed to health innovation that improves and potentially extends the lives of patients. The Company is pursuing regulatory clearance to market its first product, its proprietary CellFX System. The Company ’s CellFX System utilizes its patented Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS is a proprietary technology that delivers nano-second duration pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of completed and ongoing clinical studies.  The Company was incorporated in Nevada on May 19, 2014. On June 18, 2018, the Company reincorporated from the State of Nevada to the State of Delaware. The Company’s headquarters and manufacturing and research facility are located in Hayward, California.  The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and will need to raise additional capital to finance its operations. However, there can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its operating requirements.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies  Basis of Presentation  The accompanying unaudited condensed consolidated financial statements (“Financial Statements”) have been prepared on a basis consistent with the Company’s December 31, 2018 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements as of that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three- and nine-month periods ended September 30, 2019 are not necessarily indicative of the results to be expected for the entire year or any future periods.  Use of Estimates  The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the Financial Statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.  Recently Adopted Accounting Pronouncement  During February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“Topic 842”), which amended prior accounting standards for leases. The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019. The adoption did not materially impact the Company’s Consolidated Statement of Stockholders’ Equity or Cash Flows.  Significant Accounting Policies  There have been no material changes to the Company’s significant accounting policies during the three- and nine-month periods ended September 30, 2019, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, except for the adoption of ASU No. 2016-02, Leases , as of January 1, 2019.  Principles of Consolidation  The accompanying consolidated financial statements include the financial statements of Pulse Biosciences and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation.  Net Loss per Share  The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.  Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive.  The following outstanding stock options, warrants and restricted stock units were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:      Nine-Month Periods Ended  September 30,  2019 2018  Common stock warrants 213,485 213,485  Common stock options 3,545,491 2,858,387  Restricted stock units 111,305 222,606  Total 3,870,281 3,294,478    Reclassifications  Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassifications did not impact the Company's previously reported net loss or financial position.

Fair Value Of Financial Instrum

Fair Value Of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Fair Value Of Financial Instruments [Abstract]
Fair Value Of Financial Instruments	3. Fair Value of Financial Instruments  The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value to be classified and disclosed in one of three categories, as presented below.  Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include money market funds.  Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include commercial paper, corporate bonds, and asset-backed securities.  Level 3 - Unobservable inputs for which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. The Company did not classify any of its investments within Level 3 of the fair value hierarchy.  The following table sets forth the fair value of the Company’s financial assets measured on a recurring basis as of September 30, 2019 and December 31, 2018, respectively (in thousands):      September 30, 2019 December 31, 2018  Assets Classification Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total  Money market funds Cash and cash equivalents $ 5,912 $ — $ — $ 5,912 $ 50,703 $ — $ — $ 50,703  U.S. Treasury Securities Investments, cash and cash equivalents — 27,919 — 27,919 — 8,480 — 8,480  Total assets measured at fair value $ 5,912 $ 27,919 $ — $ 33,831 $ 50,703 $ 8,480 $ — $ 59,183  The Company did not have any financial liabilities measured on a recurring basis as of September 30, 2019 or December 31, 2018.  During the nine-month period ended September 30, 2019, there were no transfers between Level 1, Level 2 or Level 3 assets or liabilities reported at fair value on a recurring basis, and the valuation techniques used did not change compared to the Company’s established practice.

Property And Equipment, Net

Property And Equipment, Net	9 Months Ended
	Sep. 30, 2019
Property And Equipment, Net [Abstract]
Property And Equipment, Net	4. Property and Equipment, Net  Property and equipment, net consisted of the following (in thousands):     September 30, December 31,  2019 2018  Leasehold improvements $ 2,248 $ 2,248  Laboratory equipment 677 518  Furniture, fixtures, and equipment 261 248  Software 118 118  Construction in progress 506 33  3,810 3,165  Less: Accumulated depreciation (1,382) (992)  $ 2,428 $ 2,173  Depreciation expense was $0.1 million and $0.2 million for the three-month periods ended September 30, 2019 and 2018, respectively. Depreciation expense was $0.4 million and $0.5 million, for the nine-month periods ended September 30, 2019 and 2018, respectively.

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended
	Sep. 30, 2019
Intangible Assets, Net [Abstract]
Intangible Assets, Net	5 . Intangible Assets, Net  Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Company’s NPS for biomedical applications acquired from Old Dominion University Research Foundation (“ODURF”), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion University’s Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets over an estimated useful life of 12 years.  Intangible assets, net consisted of the following (in thousands):      September 30, December 31,  2019 2018  Acquired patents and licenses $ 7,985 $ 7,985  Less: Accumulated amortization (3,272) (2,772)  $ 4,713 $ 5,213  A schedule of the amortization of intangible assets for the remainder of 2019 and the succeeding five fiscal years and thereafter is as follows (in thousands):      Year Ending December 31:  2019 (remaining 3 months) $ 166  2020 665  2021 665  2022 665  2023 665  2024 665  Thereafter 1,222  $ 4,713

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2019
Goodwill [Abstract]
Goodwill	6. Goodwill  In 2014, the Company acquired three companies (the “acquisitions”) for aggregate consideration of $5.5 million. In accordance with ASC Topic 805, Business Combinations , the Company recorded goodwill of $2.8 million in connection with the acquisitions as the consideration paid exceeded the fair value of the net tangible assets and the intangible assets acquired.  The Company reviews goodwill for impairment at least annually or whenever changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. Based on the Company’s annual impairment test as of December 31, 2018 the Company determined that no impairment of goodwill existed and was not aware of any indicators of impairment at such date. In addition, there were no indicators of impairment at September 30, 2019.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2019
Accrued Expenses [Abstract]
Accrued Expenses	7. Accrued Expenses  Accrued expenses consisted of the following (in thousands):     September 30, December 31,  2019 2018  Compensation expense $ 1,057 $ 938  Accrued clinical 377 156  Professional fees 94 274  Property and equipment 219 —  Other 307 53  $ 2,054 $ 1,421

Stockholders' Equity And Stock-

Stockholders' Equity And Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity And Stock-Based Compensation [Abstract]
Stockholders' Equity And Stock-Based Compensation	8. Stockholders’ Equity and Stock-Based Compensation  Rights Offering  On October 25, 2018, the Company commenced a rights offering pursuant to which stockholders of record as of November 19, 2018, were issued, at no charge, one subscription right for each share of common stock then outstanding. Each right entitled the holder to purchase 0.19860755 share of the Company’s common stock for $12.57 per share (the “Rights Offering”).  Stockholders who exercised their rights in full were also permitted an over-subscription right to purchase additional shares of common stock that remained unsubscribed at the expiration of the Rights Offering, subject to the availability of shares and a pro rata allocation of shares among persons exercising the oversubscription right.  Upon the closing of the Rights Offering on December 6, 2018, the Rights Offering was oversubscribed. A total of 3,581,148 shares of the Company’s common stock were issued and sold in the Rights Offering for net proceeds of approximately $44.8 million. Robert W. Duggan, the Company’s Chairman of the Board of Directors and the beneficial owner of approximately 35% of the Company’s outstanding common stock prior to the Rights Offering, participated in the Rights Offering and purchased an aggregate of 3,146,226 shares for an additional investment of approximately $39.5 million.  Common Stock Warrants  In connection with a private placement offering of the Company’s common stock, par value $0.001 per share in 2014, the Company issued warrants as compensation to the placement agent to purchase a total of 299,625 shares of its common stock at a price of $2.67 per share (the “Private Placement Warrants”). The Private Placement Warrants are exercisable for period of seven years. As of September 30, 2019, there were a total of 91,876 of Private Placement Warrants outstanding. In connection with the closing of the Company’s initial public offering in 2016, the Company issued warrants as compensation to its underwriters, as representatives of the underwriters of its initial public offering to purchase a total of 574,985 shares of its common stock at a price of $5.00 per share (“the IPO Warrants”). The IPO Warrants are exercisable for a period of five years. As of September 30, 2019, there were a total of 121,609 of the IPO Warrants outstanding.  Equity Plans  2017 Equity Incentive Plan and 2017 Inducement Equity Incentive Plan  The Board of Directors of the Company (the “Board”) previously adopted, and the Company’s stockholders approved, the Company’s 2017 Equity Incentive Plan (the “2017 Plan”).  The 2017 Plan has a 10 -year term, and provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company, as the Compensation Committee of the Board may determine. Subject to an annual evergreen increase and adjustment in the case of certain capitalization events, the Company initially reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to awards under the 2017 Plan. In addition, shares remaining available under the Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), and shares reserved but not issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under the 2017 Plan. The 2017 Plan is administered by the Board’s Compensation Committee. Effective January 1, 2019, the Company’s Board authorized an increase in the number of shares of common stock available under the 2017 Plan increased by 823, 716 shares pursuant to the evergreen provision of the 2017 Plan. Pursuant to the 2017 Plan, the 2019 share increase is determined based on the least of (i) 1,200,000 shares, (ii) 4% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. As of September 30, 2019, 1,090,058 shares of common stock remained available for issuance under the 2017 Plan.  During November 2017, the Board adopted the 2017 Inducement Equity Incentive Plan (the “Inducement Plan”) and reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval.  The Inducement Plan has a 10 -year term, and provides for the grant of equity-based awards, including nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the 2017 Plan, including with respect to treatment of equity awards in the event of a “merger” or “change in control” as defined under the Inducement Plan. Options issued under the Inducement Plan may have a term up to ten years and have variable vesting provisions. New hire grants generally vest 25% annual starting upon the first anniversary of the grant. Equity-based awards issued under the Inducement Plan are only issuable to individuals not previously engaged as employees or non-employee directors of the Company prior to the Inducement Plan’s adoption date. As of September 30, 2019, there were 190,875 shares of common stock remained available for issuance under the Inducement Plan.  2017 Employee Stock Purchase Plan  The Board previously adopted and the stockholders approved the Company’s 2017 Employee Stock Purchase Plan (the “2017 ESPP”).  The 2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the 2017 ESPP. Pursuant to the 2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i) 450,000 shares, (ii) 1.5% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. During January 2019, the Board determined not to increase the number of shares of common stock available under the 2017 ESPP pursuant to the evergreen provision of the 2017 ESPP. During the nine-month period ended September 30, 2019, the Company issued 38,279 shares of common stock under the 2017 ESPP. As of September 30, 2019, there were 440,195 shares of common stock remained available for issuance under the 2017 ESPP.  A summary of stock option activity under the 2015 Plan, 2017 Plan and Inducement Plan for the nine-months ended September 30 , 2019 is presented below:      Stock Options Outstanding  Weighted-  Weighted- average  Number average remaining life  of shares exercise price (in years)  Balances — December 31, 2018 2,956,687 $ 17.04 7.6  Options granted 917,182  Options exercised (98,928)  Options canceled (64,805)  Options expired (164,645)  Balances — September 30, 2019 3,545,491 $ 16.36  Exercisable — September 30, 2019 1,864,496 $ 16.18  The table above excludes 31,875 performance stock options granted during the six-month period ended June 30, 2018 for which the performance criteria had not been established as of September 30, 2019.  Stock-based Compensation  Total stock-based compensation expense consisted of the following (in thousands):      Three-Month Periods Ended Nine-Month Periods Ended  September 30, September 30,  2019 2018 2019 2018  General and administrative $ 1,735 $ 2,483 $ 4,881 $ 7,533  Research and development 944 910 2,858 2,455  Total stock-based compensation expense $ 2,679 $ 3,393 $ 7,739 $ 9,988  The Company estimated the fair value of employee stock options on the grant date using the Black-Scholes option pricing model . The estimated fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews and, when deemed appropriate, updates the assumptions used on a periodic basis. Due to the limited trading history of the Company’s common stock, the Company utilizes a portfolio of comparable companies to estimate volatility. The fair value of employee stock options was estimated using the following weighted-average assumptions:       Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30,  2019 2018 2019 2018  Expected term in years 5.8 - 6.1 6.1 0.4 - 6.1 5.3 - 6.1  Expected volatility 70% 70% 70% 70%  Risk-free interest rate 1.4 - 1.7% 2.9% 1.4 - 2.6% 2.7 - 2.9%  Dividend yield — — — —  The Company estimated the fair value of ESPP on the grant date using the Black-Scholes option pricing model . The estimated fair value of ESPP is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews and, when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of ESPP. The fair value of ESPP was estimated using the following weighted-average assumptions:      Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30,  2019 2018 2019 2018  Expected term in years 0.5 - 1.0 0.5 - 1.0 0.5 - 1.0 0.5 - 1.0  Expected volatility 70% 70% 70% 70%  Risk-free interest rate 1.7 - 1.9% 2.3 - 2.5% 1.7 - 2.6% 1.9 - 2.5%  Dividend yield — — — —  The fair value of restricted stock unit (“RSUs”) awards is determined based on the number of units granted and the closing price of the Company’s common stock as of the grant date. The estimated fair value of RSUs is recognized on a straight-line basis over the requisite service period. During the three-month period ended June 30, 2017, the Company granted 160,974 RSUs, all of which vested, pursuant to which no shares were issued, during June 2018. Additional paid-in capital was reduced by $0.1 million for tax payments related to shares withheld in connection with the vesting of the RSUs. During the nine-month period ended September 30, 2019, the Company issued 40,582 shares. Additional paid-in capital was reduced by $0.4 million for tax payments related to shares withheld in connection with the issuance of the RSUs. The stock-based compensation expense related to these RSUs was approximately $0 and $2.1 million for the three- and nine-month periods ended September 30, 2018, respectively. For the three- and nine-month periods ended September 30, 2019, there was no stock-based compensation expense recognized related to these RSUs.  During the three-month period ended September 30, 2017, the Company granted 68,800 RSUs to certain employees which vest 50% on June 1, 2019 with the remaining 50% vesting on June 1, 2021. In the event of a change in control, these RSUs vest 100% . During the nine-month period ended September 30, 2019, the Company issued 17,456 shares in connection of the vesting of these RSUs. Additional paid-in capital was reduced by $0.2 million for tax payments related to shares withheld in connection with the vesting of the RSUs. The stock-based compensation expense related to these RSUs was approximately $0.1 million and $0.3 million for the three-month and nine-month periods ended September 30, 2019, respectively. The stock-based compensation expense related to these RSUs was approximately $0.1 million and $0.3 million for the three- and nine-month periods ended September 30, 2018, respectively.

Research Grants And Agreements

Research Grants And Agreements	9 Months Ended
	Sep. 30, 2019
Research Grants And Agreements [Abstract]
Research Grants And Agreements	9. Research Grants and Agreements  Sponsored Research Agreement  The Company may annually sponsor research activities (“SRAs”) performed by the ODURF’s Frank Reidy Center. ODURF is compensated by the Company for its conduct of each study in accordance with the budget and payment terms set forth in the applicable task order. During the quarter ended September 30, 2019, the Company agreed to sponsor $0.8 million in research during the subsequent 12 -month period funded through monthly payments made upon ODURF certifying, to the Company’s reasonable satisfaction, that ODURF has met its obligations pursuant to the specified task order and statement of work. The principal investigator may transfer funds with the budget as needed without the Company’s approval so long as the obligations of ODURF under the task order and statement of work remain unchanged and unimpaired. As of September 30, 2019, approximately $0.8 million remained payable under this agreement.  During the three-month periods ended September 30, 2019 and 2018, the Company paid and incurred costs relating to the SRAs equal to $0. 1 million and $0.1 million, respectively. During the nine-month periods ended September 30, 2019 and 2018, the Company paid and incurred costs related to the SRAs equal to $0. 6 million and $0.6 million, respectively.

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies [Abstract]
Commitments And Contingencies	10. Commitments and Contingencies  Operating Leases  During January 2017, the Company entered into a Lease (the “Existing Lease”) with Hayward Point Eden I Limited Partnership, a Delaware limited liability company (the “Landlord”) for approximately 15,697 square feet for its corporate headquarters located at 3955 Point Eden Way, Hayward, California. The lease commenced during July 2017. During May 2019, the Company entered into a First Amendment to Lease (the “Lease Amendment”) with the Landlord. The Lease Amendment amends the Existing Lease with the Landlord and provides for the expansion of the Premises by approximately 34,601 square feet (the “Expansion Premises”) and an extension of the term of the Existing Lease.  The Company will occupy the Expansion Premises in two phases. The “Phase 1” portion of the Expansion Premises contains approximately thirteen thousand two hundred and eighty ( 13,280 ) of rentable square feet and the “Phase 2” portion of the Expansion Premises contains approximately twenty-one thousand three hundred and twenty-one ( 21,321 ) of rentable square feet. Upon inclusion of the Expansion Premises, the Company will lease approximately fifty thousand two hundred and ninety-eight ( 50,298 ) rentable square feet from the Landlord (the “Entire Premises”). The Expansion Premises will also be used for the Company’s corporate headquarters and principal operating facility.  The term of the lease for the Expansion Premises is expected to commence on the date the Landlord delivers Phase 1 of the Expansion Premises to the Company “Ready for Occupancy,” as defined in the Lease Amendment (the “Expansion Commencement Date”) and runs contemporaneously with the term of the lease for the existing space (the “Lease Term”). The Lease Amendment extends the term of the lease with respect to the Entire Premises to expire on the date that is ten ( 10 ) years after the Expansion Commencement Date. In addition, under the Lease Amendment, the Company has two options to extend the Option Term, as defined in the Lease Amendment, by seven ( 7 ) years upon written notice not more than twelve ( 12 ) months nor less than nine ( 9 ) months prior to the expiration of the lease, with monthly payments equal to the “Fair Rental Value” as defined in the Existing Lease.  The Company will continue to pay base monthly rent for the existing premises in accordance with the terms of the Existing Lease. The Expansion Premises’ base monthly rent shall be abated for the first four ( 4 ) months of the Lease Term and thereafter will be $2.25 per rentable square foot for the Expansion Premises, with specified annual increases occurring thereafter until reaching approximately $3.819 per ren table square foot during the last six (6) months of the Lease Term. The total base rent beginning on the Expansion Commencement Date through the minimum term of the lease is not calculable at this time since the total base rent will depend on the date the Phase 2 portion of the Expansion Premises is “Ready for Occupancy.” In addition to base rent, the Company will continue to be required to reimburse the Landlord for certain expenses during the Lease Term. Under the Lease Amendment, the Company is required to increase its refundable security deposit by $264,264.88 to equal $364,937.68 .  The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments.  The Company evaluated the Lease Amendment under Topic 842 and concluded that the Lease Amendment meets the definition of a lease modification as it extends the term of the Existing Lease and increases the Company’s leased premise. As the Company determined that the increase in payments under the Lease Amendment is not commensurate with the additional right-of-use assets provided in the modified lease, the modified lease is not accounted for as a separate contract. The remeasurement for the modification resulted in an increase in total lease lability of approximately $2.4 million, increase in right-of-use assets of $1.1 million, and other assets of $1.3 million.  Information related to the Company's right-of-use assets and related lease liabilities were as follows (in thousands except for remaining lease term and discount rate):      Cash paid for operating lease liabilities $ 263  Right-of-use assets recognized in exchange for new lease obligations 1,190   Current operating lease liabilities 177  Non-current operating lease liabilities 3,674  Total lease liabilities $ 3,851   Weighted-average remaining lease term 10.09  Weighted-average discount rate 10%   Maturities of lease liabilities as of September 30, 2019 were as follows (in thousands):     Year Ending December 31:  2019 (remaining 3 months) $ 136  2020 554  2021 574  2022 581  2023 577  Thereafter 3,792  Total lease payments 6,214  Less imputed interest (2,363)  Total lease liabilities $ 3,851  During the three-month periods ended September 30 , 2019 and 2018, rent expense, including common area maintenance charges, was approximately $0.1 million and $57,000 , respectively. During the nine-month periods ended September 30 , 2019 and 2018, rent expense, including common area maintenance charges, was approximately $0.2 million and $0.2 million , respectively.  Legal Proceedings  The Company maintains indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law.  From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes and other matters relating to various claims that arise in the normal course of the Company’s business. The Company currently believes that these ordinary course matters are not material to the financial statements of the business; however, the results of litigation and claims are inherently unpredictable.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions  Kenneth A. Clark, a director of the Company since November 2017, is a member of the law firm of Wilson Sonsini Goodrich and Rosati (“WSGR”), which also serves as the outside corporate counsel to the Company. During the three- and nine-month periods ended September 30, 2019, the Company incurred expenses reported in general and administrative expenses in the consolidated statement of operations for legal services rendered by WSGR totaling approximately $ 0.1 million and $0.3 million , respectively. During the three- and nine-month periods ended September 30, 2018, the Company incurred expenses for legal services rendered by WSGR totaling approximately $0.3 million and $1.1 million, respectively. 

Summary Of Significant Accoun_2

Summary Of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2019
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation  The accompanying unaudited condensed consolidated financial statements (“Financial Statements”) have been prepared on a basis consistent with the Company’s December 31, 2018 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements as of that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three- and nine-month periods ended September 30, 2019 are not necessarily indicative of the results to be expected for the entire year or any future periods. 
Use Of Estimates	Use of Estimates  The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the Financial Statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement  During February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“Topic 842”), which amended prior accounting standards for leases. The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019. The adoption did not materially impact the Company’s Consolidated Statement of Stockholders’ Equity or Cash Flows.
Significant Accounting Policies	Significant Accounting Policies  There have been no material changes to the Company’s significant accounting policies during the three- and nine-month periods ended September 30, 2019, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, except for the adoption of ASU No. 2016-02, Leases , as of January 1, 2019.
Principles of Consolidation	Principles of Consolidation  The accompanying consolidated financial statements include the financial statements of Pulse Biosciences and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation.
Net Loss Per Share	Net Loss per Share  The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.  Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive.  The following outstanding stock options, warrants and restricted stock units were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:      Nine-Month Periods Ended  September 30,  2019 2018  Common stock warrants 213,485 213,485  Common stock options 3,545,491 2,858,387  Restricted stock units 111,305 222,606  Total 3,870,281 3,294,478   
Reclassifications	Reclassifications  Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassifications did not impact the Company's previously reported net loss or financial position.

Summary Of Significant Accoun_3

Summary Of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Summary Of Significant Accounting Policies [Abstract]
Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share	   Nine-Month Periods Ended  September 30,  2019 2018  Common stock warrants 213,485 213,485  Common stock options 3,545,491 2,858,387  Restricted stock units 111,305 222,606  Total 3,870,281 3,294,478 

Fair Value Of Financial Instr_2

Fair Value Of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Of Financial Instruments [Abstract]
Fair Value Of Financial Assets Measured On A Recurring Basis	   September 30, 2019 December 31, 2018  Assets Classification Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total  Money market funds Cash and cash equivalents $ 5,912 $ — $ — $ 5,912 $ 50,703 $ — $ — $ 50,703  U.S. Treasury Securities Investments, cash and cash equivalents — 27,919 — 27,919 — 8,480 — 8,480  Total assets measured at fair value $ 5,912 $ 27,919 $ — $ 33,831 $ 50,703 $ 8,480 $ — $ 59,183 

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2019
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment, Net	   September 30, December 31,  2019 2018  Leasehold improvements $ 2,248 $ 2,248  Laboratory equipment 677 518  Furniture, fixtures, and equipment 261 248  Software 118 118  Construction in progress 506 33  3,810 3,165  Less: Accumulated depreciation (1,382) (992)  $ 2,428 $ 2,173 

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2019
Intangible Assets, Net [Abstract]
Schedule Of Intangible Assets, Net	   September 30, December 31,  2019 2018  Acquired patents and licenses $ 7,985 $ 7,985  Less: Accumulated amortization (3,272) (2,772)  $ 4,713 $ 5,213 
Schedule Of Amortization Of Intangible Assets	   Year Ending December 31:  2019 (remaining 3 months) $ 166  2020 665  2021 665  2022 665  2023 665  2024 665  Thereafter 1,222  $ 4,713 

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2019
Accrued Expenses [Abstract]
Schedule Of Accrued Expenses	   September 30, December 31,  2019 2018  Compensation expense $ 1,057 $ 938  Accrued clinical 377 156  Professional fees 94 274  Property and equipment 219 —  Other 307 53  $ 2,054 $ 1,421 

Stockholders' Equity And Stoc_2

Stockholders' Equity And Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity [Line Items]
Summary Of Stock Option Activity	   Stock Options Outstanding  Weighted-  Weighted- average  Number average remaining life  of shares exercise price (in years)  Balances — December 31, 2018 2,956,687 $ 17.04 7.6  Options granted 917,182  Options exercised (98,928)  Options canceled (64,805)  Options expired (164,645)  Balances — September 30, 2019 3,545,491 $ 16.36  Exercisable — September 30, 2019 1,864,496 $ 16.18 
Summary Of Stock-Based Compensation Expense	   Three-Month Periods Ended Nine-Month Periods Ended  September 30, September 30,  2019 2018 2019 2018  General and administrative $ 1,735 $ 2,483 $ 4,881 $ 7,533  Research and development 944 910 2,858 2,455  Total stock-based compensation expense $ 2,679 $ 3,393 $ 7,739 $ 9,988 
Options [Member]
Stockholders' Equity [Line Items]
Schedule Of Fair Value Of Employee Stock Options	   Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30,  2019 2018 2019 2018  Expected term in years 5.8 - 6.1 6.1 0.4 - 6.1 5.3 - 6.1  Expected volatility 70% 70% 70% 70%  Risk-free interest rate 1.4 - 1.7% 2.9% 1.4 - 2.6% 2.7 - 2.9%  Dividend yield — — — — 
2017 Employee Stock Purchase Plan [Member]
Stockholders' Equity [Line Items]
Schedule Of Fair Value Of Employee Stock Options	   Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30,  2019 2018 2019 2018  Expected term in years 0.5 - 1.0 0.5 - 1.0 0.5 - 1.0 0.5 - 1.0  Expected volatility 70% 70% 70% 70%  Risk-free interest rate 1.7 - 1.9% 2.3 - 2.5% 1.7 - 2.6% 1.9 - 2.5%  Dividend yield — — — — 

Commitments And Contingencies (

Commitments And Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies [Abstract]
Schedule Of Information Related To Right-Of-Use Assets And Lease Liabilities	   Cash paid for operating lease liabilities $ 263  Right-of-use assets recognized in exchange for new lease obligations 1,190   Current operating lease liabilities 177  Non-current operating lease liabilities 3,674  Total lease liabilities $ 3,851   Weighted-average remaining lease term 10.09  Weighted-average discount rate 10%  
Schedule Of Future Minimum Lease Payments	  Year Ending December 31:  2019 (remaining 3 months) $ 136  2020 554  2021 574  2022 581  2023 577  Thereafter 3,792  Total lease payments 6,214  Less imputed interest (2,363)  Total lease liabilities $ 3,851 

Description Of The Business (Na

Description Of The Business (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Subsidiary, Sale of Stock [Line Items]
Net loss	$ (11,746)	$ (10,761)	$ (33,183)	$ (28,592)
Cash used in operating activities			(24,989)	$ (17,588)
Accumulated deficit	$ (108,901)		$ (108,901)		$ (75,718)

Summary Of Significant Accoun_4

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Summary Of Significant Accounting Policies [Line Items]
Right-of-use assets	$ 1,190
Accounting Standards Update 2016-02 [Member]
Summary Of Significant Accounting Policies [Line Items]
Right-of-use assets		$ 100

Summary Of Significant Accoun_5

Summary Of Significant Accounting Policies (Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,870,281	3,294,478
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	213,485	213,485
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,545,491	2,858,387
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	111,305	222,606

Fair Value Of Financial Instr_3

Fair Value Of Financial Instruments (Narrative) (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Fair Value Of Financial Instruments [Abstract]
Liabilities measured at fair value	$ 0	$ 0
Transfers between level 1, 2, or 3	$ 0

Fair Value Of Financial Instr_4

Fair Value Of Financial Instruments (Fair Value Of Financial Assets Measured On A Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
ASSETS
Total assets measured at fair value	$ 33,831	$ 59,183
Cash and cash equivalents [Member] | Money market funds [Member]
ASSETS
Total cash and cash equivalents	5,912	50,703
Investments, cash and cash equivalents [Member] | U.S. Treasury Securities [Member]
ASSETS
Total investments	27,919	8,480
Level 1 [Member]
ASSETS
Total assets measured at fair value	5,912	50,703
Level 1 [Member] | Cash and cash equivalents [Member] | Money market funds [Member]
ASSETS
Total cash and cash equivalents	5,912	50,703
Level 2 [Member]
ASSETS
Total assets measured at fair value	27,919	8,480
Level 2 [Member] | Investments, cash and cash equivalents [Member] | U.S. Treasury Securities [Member]
ASSETS
Total investments	$ 27,919	$ 8,480

Property And Equipment, Net (Na

Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Property And Equipment, Net [Abstract]
Depreciation expense	$ 100	$ 200	$ 390	$ 474

Property And Equipment, Net (Sc

Property And Equipment, Net (Schedule Of Property And Equipment, Net) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 3,810	$ 3,165
Less: Accumulated depreciation	(1,382)	(992)
Equipment, net	2,428	2,173
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	2,248	2,248
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	677	518
Furniture, Fixtures, And Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	261	248
Software [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	118	118
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 506	$ 33

Intangible Assets, Net (Narrati

Intangible Assets, Net (Narrative) (Details)	9 Months Ended
	Sep. 30, 2019
Intangible Assets, Net [Abstract]
Intangible asset useful life	12 years

Intangible Assets, Net (Schedul

Intangible Assets, Net (Schedule Of Intangible Assets, Net) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Intangible Assets, Net [Abstract]
Intangible assets, gross	$ 7,985	$ 7,985
Less: Accumulated amortization	(3,272)	(2,772)
Intangible assets, net	$ 4,713	$ 5,213

Intangible Assets, Net (Sched_2

Intangible Assets, Net (Schedule Of Amortization Of Intangible Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Intangible Assets, Net [Abstract]
2019 (remaining 3 months)	$ 166
2020	665
2021	665
2022	665
2023	665
2024	665
Thereafter	1,222
Intangible assets, net	$ 4,713	$ 5,213

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2014
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Goodwill	$ 2,791,000	$ 2,791,000	$ 2,800,000
Goodwill impairment	$ 0	$ 0
TPI, BEM And NB [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Aggregate consideration			$ 5,500,000

Accrued Expenses (Schedule Of A

Accrued Expenses (Schedule Of Accrued Expenses) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued Expenses [Abstract]
Compensation expense	$ 1,057	$ 938
Accrued clinical	377	156
Professional fees	94	274
Property and equipment	219
Other	307	53
Accrued expenses	$ 2,054	$ 1,421

Stockholders' Equity And Stoc_3

Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($)	Jan. 01, 2019	Dec. 06, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Oct. 25, 2018	Nov. 30, 2017	Dec. 31, 2016	Dec. 31, 2014
Stockholders' Equity [Line Items]
Common stock, par value			$ 0.001					$ 0.001		$ 0.001
Proceeds from issuance of common stock under employee stock purchase plan								$ 423,000	$ 327,000
Common stock, shares issued			20,788,000					20,788,000		20,593,000
Total stock-based compensation expense			$ 2,679,000	$ 3,393,000				$ 7,739,000	9,988,000
Cash received from option exercises								$ 272,000	423,000
2017 Employee Stock Purchase Plan [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued			38,279					38,279
Shares authorized			250,000					250,000
Increase in shares available for issuance threshold of common stock outstanding, number of shares								450,000
Increase in shares available for issuance threshold of common stock outstanding, percent outstanding								1.50%
Shares available for grant			440,195					440,195
2017 Inducement Equity Incentive Plan [Member]
Stockholders' Equity [Line Items]
Term period								10 years
Shares authorized												1,000,000
Shares available for grant			190,875					190,875
2017 Plan [Member]
Stockholders' Equity [Line Items]
Term period								10 years
Shares authorized			1,500,000					1,500,000
Additional common stock reserved for issuance	823,716
Increase in shares available for issuance threshold of common stock outstanding, number of shares								1,200,000
Increase in shares available for issuance threshold of common stock outstanding, percent outstanding								4.00%
Shares available for grant			1,090,058					1,090,058
First Vesting Portion [Member] | 2017 Inducement Equity Incentive Plan [Member]
Stockholders' Equity [Line Items]
Vesting percentage								25.00%
Sales, general and administrative [Member]
Stockholders' Equity [Line Items]
Total stock-based compensation expense			$ 1,735,000	2,483,000				$ 4,881,000	7,533,000
Research and development [Member]
Stockholders' Equity [Line Items]
Total stock-based compensation expense			$ 944,000	910,000				$ 2,858,000	2,455,000
Options [Member]
Stockholders' Equity [Line Items]
Options granted								917,182
Warrants exercised								98,928
Exercise price			$ 16.18					$ 16.18
Restricted Stock Units [Member]
Stockholders' Equity [Line Items]
Units granted during period						160,974		40,582
Reduction to APIC from shares withheld for tax						$ 100,000		$ 400,000
Total stock-based compensation expense			$ 0	0				$ 0	2,100,000
Performance Shares [Member]
Stockholders' Equity [Line Items]
Options granted							31,875
Private Placement [Member]
Stockholders' Equity [Line Items]
Common stock, par value														$ 0.001
Certain Employees [Member] | Restricted Stock Units [Member]
Stockholders' Equity [Line Items]
Units granted during period					68,800			17,456
Reduction to APIC from shares withheld for tax								$ 200,000
Total stock-based compensation expense			$ 100,000	$ 100,000				$ 300,000	$ 300,000
Certain Employees [Member] | Restricted Stock Units [Member] | First Vesting Portion [Member]
Stockholders' Equity [Line Items]
Vesting percentage					50.00%
Certain Employees [Member] | Restricted Stock Units [Member] | Second Vesting Portion [Member]
Stockholders' Equity [Line Items]
Vesting percentage					50.00%
Certain Employees [Member] | Restricted Stock Units [Member] | Change In Control [Member]
Stockholders' Equity [Line Items]
Vesting percentage					100.00%
Common Stock
Stockholders' Equity [Line Items]
Warrants exercised				62,000				99,000	117,000
Common Stock | Rights Offering [Member]
Stockholders' Equity [Line Items]
Net proceeds		$ 44,800,000
Right entitlement to holder		3,581,148									0.19860755
Exercise price of warrants/rights											$ 12.57
Common Stock | Warrants [Member]
Stockholders' Equity [Line Items]
Warrants exercised				24,000					24,000
Common Stock | Chairman, Robert W. Duggan [Member] | Rights Offering [Member]
Stockholders' Equity [Line Items]
Ownership percentage		35.00%
Shares purchased		3,146,226
Investment		$ 39,500,000
MDB Capital Group, LLC [Member] | Initial Public Offering [Member]
Stockholders' Equity [Line Items]
Price per share													$ 5
Warrants/rights outstanding			121,609					121,609
Exercisable period of warrants or rights								5 years
Number of common shares called by issuance of warrants													574,985
MDB Capital Group, LLC [Member] | Private Placement [Member]
Stockholders' Equity [Line Items]
Price per share														$ 2.67
Warrants/rights outstanding			91,876					91,876
Exercisable period of warrants or rights								7 years
Number of common shares called by issuance of warrants														299,625

Stockholders' Equity And Stoc_4

Stockholders' Equity And Stock-Based Compensation (Summary Of Stock Option Activity) (Details) - Options [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Beginning Balance, Number of shares	2,956,687
Options granted, Number of shares	917,182
Options exercised, Number of shares	(98,928)
Options canceled, Number of shares	(64,805)
Options expired, Number of shares	(164,645)
Ending Balance, Number of shares	3,545,491	2,956,687
Exercisable, Number of shares	1,864,496
Beginning Balance, Weighted average exercise price per share	$ 17.04
Options granted, Weighted average exercise price per share
Options exercised, Weighted average exercise price per share
Options canceled, Weighted average exercise price per share
Options expired, Weighted average exercise price per share
Ending Balance, Weighted average exercise price per share	16.36	$ 17.04
Exercisable, Weighted average exercise price per share	$ 16.18
Weighted average remaining life		7 years 7 months 6 days

Stockholders' Equity And Stoc_5

Stockholders' Equity And Stock-Based Compensation (Schedule Of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 2,679	$ 3,393	$ 7,739	$ 9,988
Sales, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,735	2,483	4,881	7,533
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 944	$ 910	$ 2,858	$ 2,455

Stockholders' Equity And Stoc_6

Stockholders' Equity And Stock-Based Compensation (Schedule Of Fair Value Of Employee Stock Options) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years		6 years 1 month 6 days
Expected volatility	70.00%	70.00%	70.00%	70.00%
Risk-free interest rate		2.90%
Risk-free interest rate, minimum	1.40%		1.40%	2.70%
Risk-free interest rate, maximum	1.70%		2.60%	2.90%
Dividend yield
Options [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	5 years 9 months 18 days		4 months 24 days	5 years 3 months 18 days
Options [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 1 month 6 days		6 years 1 month 6 days	6 years 1 month 6 days
2017 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	70.00%	70.00%	70.00%	70.00%
Risk-free interest rate, minimum	1.70%	2.30%	1.70%	1.90%
Risk-free interest rate, maximum	1.90%	2.50%	2.60%	2.50%
Dividend yield
2017 Employee Stock Purchase Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 months	6 months	6 months	6 months
2017 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	1 year	1 year	1 year	1 year

Research Grants And Agreements

Research Grants And Agreements (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	$ 6,192	$ 5,038	$ 18,371	$ 12,174
Sponsored Research Agreement ("SRA") [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	100	$ 100	$ 600	$ 600
ODURF [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Period of time for Sponsored Research Agreement ("SRA")			12 months
ODURF [Member] | Sponsored Research Agreement ("SRA") [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	800
Remaining sponsorship	$ 800		$ 800

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)ft²	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)ft²	Sep. 30, 2018USD ($)	May 31, 2019ft²	Jan. 01, 2019USD ($)	Jan. 31, 2017ft²
Commitments and Contingencies [Line Items]
Area Of Lease | ft²	50,298		50,298				15,697
Lease term	10 years		10 years
Lease renewable term	7 years		7 years
Period of base rent abatement			4 months
Increase in security deposit			$ 264,264.88
Security deposit	$ 364,937.68		364,937.68
Right-of-use assets	1,190,000		1,190,000
Increase in other assets			2,734,000
Rent expense, including common area maintenance charges	$ 100,000	$ 57,000	$ 200,000	$ 200,000
Maximum [Member]
Commitments and Contingencies [Line Items]
Written notice period for right to extend lease term			12 months
Minimum [Member]
Commitments and Contingencies [Line Items]
Written notice period for right to extend lease term			9 months
Lease Amendment [Member]
Commitments and Contingencies [Line Items]
Area Of Lease | ft²					34,601
Lease Amendment - Phase One [Member]
Commitments and Contingencies [Line Items]
Area Of Lease | ft²	13,280		13,280
Lease Amendment - Phase Two [Member]
Commitments and Contingencies [Line Items]
Area Of Lease | ft²	21,321		21,321
Expansion Premises [Member]
Commitments and Contingencies [Line Items]
Lease term, base monthly rent per square foot	$ 2.25		$ 2.25
Last Six Months Of Lease [Member]
Commitments and Contingencies [Line Items]
Lease term, base monthly rent per square foot	$ 3.819		3.819
Accounting Standards Update 2016-02 [Member]
Commitments and Contingencies [Line Items]
Right-of-use assets						$ 100,000
Increase in total lease liability			2,400,000
Increase in right-of-use assets			1,100,000
Increase in other assets			$ 1,300,000

Commitments And Contingencies_3

Commitments And Contingencies (Schedule Of Information Related To Right-Of-Use Assets And Lease Liabilities) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Commitments And Contingencies [Abstract]
Cash paid for operating lease liabilities	$ 263
Right-of-use assets recognized in exchange for new lease obligations	1,190
Current operating lease liabilities	177
Non-current operating lease liabilities	3,674
Total lease liabilities	$ 3,851
Weighted average remaining lease term	10 years 1 month 2 days
Weighted average discount rate	10.00%

Commitments And Contingencies_4

Commitments And Contingencies (Schedule Of Future Minimum Lease Payments) (Details) $ in Thousands	Sep. 30, 2019USD ($)
Commitments And Contingencies [Abstract]
2019 (remaining 3 months)	$ 136
2020	554
2021	574
2022	581
2023	577
Thereafter	3,792
Total minimum lease payments	6,214
Less imputed interest	(2,363)
Total operating lease liabilities	$ 3,851

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Wilson Sonsini Goodrich And Rosati (WSGR) [Member]
Related Party Transaction [Line Items]
Related party expenses	$ 0.1	$ 0.3	$ 0.3	$ 1.1